



NIH PUBLIC ACCESS

Author Manuscript

Pharmacogenomics. Author manuscript; available in PMC 2011 May 1.

Published in final edited form as:

Pharmacogenomics. 2010 July ; 11(7): 1003–1010. doi:10.2217/pgs.10.95.

Irinotecan pharmacogenomics

Sharon Marsh[†] and Janelle M Hoskins¹¹UNC Institute for Pharmacogenomics & Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

Abstract

Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (*UGT1A1**28) is strongly associated with toxicity; however, this link is dose dependent. Variations in other pharmacokinetic genes, particularly the transporter *ABCC2*, also contribute to irinotecan toxicity. In addition, recent studies have shown that pharmacodynamic genes such as *TDPI* and *XRCC1* can also play a role in both toxicity and response.

Keywords

ABCC2; irinotecan; pharmacogenomics; TDPI; toxicity; UGT1A1; XRCC1

Camptothecin, a cytotoxic agent found in *Camptotheca acuminata*, was developed as an anticancer agent in the early 1970s [1–3]. Its mechanism of action is to bind to the DNA/topoisomerase I complex during DNA replication, preventing the resealing of single-strand breaks. Ultimately, the replication machinery collides with the camptothecin/topoisomerase I complex, shattering the DNA [4]. However, camptothecin is insoluble and attempts to address this both reduced the efficacy and increased the toxicity of the drug.

Camptothecin analogs were developed in the 1990s to circumvent the solubility problems. Irinotecan (also known as CPT-11, Camptosar®) is an analog approved for first-line therapy of advanced colorectal cancer in combination with 5-fluorouracil and/or leucovorin. In addition, irinotecan/cisplatin combination therapy is used for other cancers, for example lung and ovarian [5–6]. Recent studies have involved the combination of irinotecan with bevacizumab or cetuximab [1–2,7–8].

Diarrhea and neutropenia are major limiting factors for irinotecan, with up to 36% of patients experiencing severe, potentially life-threatening toxicities [9]. Methods such as pharmacogenomics to prospectively screen patients for DNA variations (Table 1) prior to selecting irinotecan therapy or dose would help improve patient care and reduce healthcare costs [10–12].

© 2010 Future Medicine Ltd

[†]Author for correspondence: Faculty of Pharmacy & Pharmaceutical Sciences, 3126 Dentistry/Pharmacy Centre, University of Alberta, Edmonton, AB T6G 2N8, Canada Tel.: +1 780 492 2266 Fax: +1 780 492 1217 smarsh@pharmacy.ualberta.ca.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Irinotecan pharmacokinetics

Metabolism

Irinotecan is a prodrug, metabolized into the active form, SN-38, via human carboxylesterases CES1 and CES2. CYP3A4 converts irinotecan into the inactive metabolite, APC. The active SN-38 can be subsequently inactivated through glucuronidation via members of the UDP-glucuronosyltransferase family [12]. UGT1A enzymes are a product of alternative splicing from the *UGT1A* locus located on chromosome 2q37. A total of 13 *UGT1A* genes are encoded at this locus (including four pseudogenes). Each UGT1A enzyme has a unique promoter and a unique exon 1, while the remaining four exons are shared with all members of the UGT1A family [13].

Metabolism pharmacogenomics

Carboxylesterases—Carboxylesterase 2 is the key enzyme responsible for hydrolyzing CPT-11 to the active SN-38 form [14]. CES2 expression is highly variable among individuals [15–16], and *in vitro* studies suggest that increased CES2 expression leads to increased irinotecan metabolism [17]. However, extensive assessment of the *CES2* gene did not identify any functional polymorphisms [18–19], and characterization of a common promoter variant in the 5'-UTR of *CES2* (referred to as 830C>G; located at –171C>G) did not identify any associations with CES2 expression or catalytic activity, or irinotecan toxicity or outcome [20]. *CES2* is, however, controlled by three distinct promoter regions [21], and it is possible that control of promoter choice may explain some of the individual variation in CES2 expression.

CES1 plays a minor role in irinotecan metabolism, and extensive resequencing of *CES1* also did not identify any functional polymorphisms [18]. However, in a Japanese hypertensive patient population, a –816A>C variant in the *CES1* promoter region has been reported to affect *CES1* promoter activity [22], but this remains to be assessed in the context of irinotecan metabolism.

CYP3A4—CYP3A4 inactivates irinotecan through conversion into the metabolite APC [23]. While there is no evidence of variants in the *CYP3A4* gene providing a useful screen for APC conversion, the interindividual variability in CYP3A4 activity can be exploited for irinotecan dosing [24].

UGT1A1—The most comprehensively studied genetic marker linked to toxicity from irinotecan therapy is found in the UDP-glucuronosyltransferase gene, *UGT1A1*. The UGT1A1 enzyme is responsible for hepatic bilirubin glucuronidation, and reduced UGT1A1 expression leads to Gilbert's syndrome [25]. Expression of UGT1A1 is, in part, controlled by a polymorphic dinucleotide repeat within the *UGT1A1* promoter TATA element consisting of between five and eight copies of a TA repeat ($[TA]_nTAA$), with the $(TA)_6TAA$ allele the most common (considered wild-type) and $(TA)_7TAA$ the most frequently recorded variant allele (usually denoted *UGT1A1**28) [26]. The longer the repeat allele, the lower the corresponding *UGT1A1* gene expression, with patients carrying the $(TA)_7TAA$ and $(TA)_8TAA$ alleles having significantly lower UGT1A1 expression. The frequency of the *UGT1A1**28 allele has been assessed worldwide and ranges from approximately 15% in Asians to 45% in Africans. It is also found in 26–38% of Caucasians, African-Americans and Hispanics [27–29]. As increasing the number of TA repeats decreases UGT1A1 expression, the presence of more than six TA repeats in the *UGT1A1* promoter region leads to reduced glucuronidation, including reduced SN-38G formation. This results in an excess build-up of SN-38, leading to toxicity [12,25,30].

Early studies confirmed the link between *UGT1A1**28 and irinotecan toxicity, specifically diarrhea and neutropenia [27,31], and a retrospective analysis of DNA from 524 metastatic colorectal cancer patients on the N9741 study also associated *UGT1A1**28 with the incidence of toxicities (neutropenia, febrile neutropenia and vomiting) [32]. Furthermore, a prospective study of 66 patients with advanced disease treated with irinotecan found that patients homozygous for *UGT1A1**28 had a significantly greater risk of grade IV neutropenia compared with patients with at least one wild-type allele [33].

UGT1A1 in the clinic—In 2005, the US FDA approved a genetic test for *UGT1A1**28 [34] and altered the irinotecan package insert to include toxicity and dosing warnings relating to the *UGT1A1**28 allele [35]. This marked a significant step towards incorporating pharmacogenomics into clinical practice. However, 5 years on, concerns still remain over the specific irinotecan dose required based on genotype [36–37]. A subsequent study has identified that the relationship between *UGT1A1**28 and irinotecan toxicity is dependent on the irinotecan regimen used, rendering *UGT1A1**28 unsuitable as a marker for toxicity with lower doses (50–180 mg/m²). For moderate-to-high doses (200–350 mg/m²), the risk of severe hematological toxicity in patients homozygous for *UGT1A1**28 is 27.8-times higher than for patients with at least one wild-type allele [38]. Furthermore, a European study confirmed that toxicity from low-dose irinotecan was not affected by the *UGT1A1**28 variant [39]. Consequently, it appears necessary to further amend the irinotecan package insert to include dose/genotype guidelines. A recent prospective European study of 59 patients showed that when *UGT1A1**28 homozygous patients are excluded; the standard 180 mg/m² dose is significantly lower than the irinotecan dose that can be tolerated [40]. Dosing information from a Japanese Phase I study of 27 patients receiving irinotecan and doxifluridine has suggested a starting dose of 70 mg/m² for patients heterozygous for *UGT1A1**28. No homozygous patients were identified in this study [41].

Other *UGT1A1* polymorphisms—There are other significant polymorphisms in the *UGT1A1* gene. Patients with haplotypes containing both the –3156G>A variant and *UGT1A1**28 experienced significantly higher incidence of severe neutropenia compared with patients with haplotypes not containing –3156G>A [33], and in the N9741 study the *UGT1A1* –3156 variant was associated with a significantly increased risk of neutropenia [32]. In Caucasian populations, the *28 and –3156 alleles are in strong linkage disequilibrium [33].

In Asian populations where the frequency of *UGT1A1**28 is low [42], other *UGT1A1* variants can also play a role in irinotecan toxicity [12,43–50]. For example, in Korean patients with non-small-cell lung cancer treated with irinotecan-containing therapy, there were associations between the exon 1 polymorphism *UGT1A1**6 (G71R), irinotecan pharmacokinetics, and toxicity from irinotecan therapy [47]. In a further study of 88 Japanese cancer patients receiving irinotecan, two haplotype groups were associated with reduced area under the curve (AUC) ratios of SN-38G to SN-38, which is predicted to have an effect on irinotecan toxicity. These haplotypes were denoted *28 (containing the *UGT1A1**28 allele) and *6 (containing the exon 1 G71R polymorphism) [44]. Patients with the *6 haplotype alone did not show significant variation in their AUC ratios; however, patients with one *6 haplotype and one *28 haplotype had significantly lower AUC ratios compared with patients with homozygous wild-type *UGT1A1* [44].

Other *UGT1A* genes—Variants in *UGT1A7* and *UGT1A9* are also associated with SN-38 glucuronidation [51] and irinotecan toxicities (particularly diarrhea) [47,52,53], although these studies require further exploration. *UGT1A7**3 has been associated with hematologic toxicity in metastatic colorectal cancer patients treated with irinotecan [54]. Furthermore,

*UGT1A7**2 and *3, as well as *UGT1A9* -118(dT) alleles, were associated with response to irinotecan [52].

Transport

Irinotecan and SN-38 may be transported out of the cell via members of the ATP-binding cassette transporter family [55], specifically ABCB1 (MDR1; P-glycoprotein), ABCC2 (CMOAT; MRP2) and ABCG2 (BCRP). In addition, glucuronidated SN-38 can be removed from the cell by ABCC2 (Figure 1).

Transport pharmacogenomics

ABCB1—In 65 patients treated with irinotecan, the common *ABCB1* 1236C>T variant caused significantly decreased clearance of irinotecan [56]. *ABCB1* 3435C>T was associated with diarrhea caused by irinotecan-containing therapy in a subset of 87 patients from a Phase III small-cell lung cancer trial [57]. In a further study, a haplotype containing the three most commonly studied *ABCB1* polymorphisms (1236C>T, 2677G>T and 3435C>T) was associated with reduced renal clearance in 49 Asian patients receiving irinotecan [58]. The *ABCB1* haplotype was also associated with response and survival in 140 colorectal cancer patients from the Nordic VI trial [59]. In the same study, *ABCB1* 3435C>T was also predictive of early toxic events [59].

ABCC2—In 64 patients with solid tumors treated with irinotecan, a significant correlation was observed with irinotecan and metabolite clearance, and the 3972T>C polymorphism [43], which was also associated with toxicity [60]. *ABCC2* -24T homozygotes and 3972T homozygotes also experienced significantly better response rates and progression-free survival in non-small-cell lung cancer patients receiving irinotecan and cisplatin [61]. In addition, a haplotype in the multidrug transporter *ABCC2* is associated with toxicity in patients lacking *UGT1A1**28 [46,62–63], suggesting that this haplotype could be a secondary screen for patients who are wild-type for *UGT1A1*, to further reduce the risk of toxicity.

ABCG2—Cell lines overexpressing ABCG2 are resistant to several topoisomerase I inhibitors, including irinotecan [64] and SN-38 [65]. The *ABCG2* variant 421C>A (Q141K) reduced *ABCG2* gene expression and caused irinotecan resistance in cancer cell lines [66] and neutropenia in 55 patients receiving irinotecan monotherapy when assessed as a haplotype with *ABCG2* IVS12 +49G>T [67]. Alone, the *ABCG2* 421C>A variant was not associated with toxicity [49,61]. A further polymorphism, *ABCG2* 34G>A, was significantly associated with diarrhea in 107 cancer patients [60] but was not associated with toxicity or outcome in 107 non-small-cell lung cancer patients [61].

Irinotecan pharmacodynamics

Topoisomerase I is the target for SN-38, and several downstream genes have been associated with camptothecin sensitivity, and are consequently included in the irinotecan pathway (Figure 1) including *XRCC1* [68], *ADPRT* [69], *TDPI* [70], *CDC45L* [71] and *NF-κB1* [72–73].

Pharmacodynamics & pharmacogenomics

A retrospective analysis of 107 colorectal cancer patients identified a significant association with *TDPI* IVS12 +79T>G and grade 3/4 neutropenia, and the *TDPI* variant and an *XRCC1* haplotype and response to irinotecan [74]. Associations with toxicity were not seen in a follow-up study of 85 cancer patients [75], although the dose of irinotecan was higher (300–350 mg/m² compared with a median of 180 mg/m² in [74]), and no significant association

with *XRCC1* R399Q and toxicity was seen in 18 colorectal cancer patients [76]. However, the variant *XRCC1* R399Q was associated with overall survival in 43 Turkish metastatic colorectal cancer patients [77]. Assessment of irinotecan pharmacodynamics in the context of pharmacogenomics is in its infancy, and subsequent validation experiments are required.

Future perspective

Toxicity is a major dose-limiting, life-threatening side effect from irinotecan chemotherapy. There are comprehensive data to suggest that *UGT1A1**28 may provide a genetic marker that patients can be screened for prior to irinotecan therapy and/or dose selection, and this has the potential to be a cost-effective screening approach [78]. However, a decade on from the initial association with toxicity, there are still questions remaining about how to interpret the genetic information [37]. Moreover, *UGT1A1**28 does not account for all the toxicity seen from irinotecan therapy. Consequently, although screening for this allele can identify patients at risk, the lack of *UGT1A1**28 does not preclude the chances of a patient experiencing severe toxicity.

Alongside variants in other *UGT1A* genes, transporters, and pharmacodynamic genes (Table 1), *in vitro* studies have shown that altered expression of PXR (encoded by the *NR1I2* gene) can affect SN-38 glucuronidation [79]. Consequently, variation in the *NR1I2* gene should be explored in the context of irinotecan therapy. Recent work has also suggested that epigenetic factors, such as methylation, may also play a role in altering *UGT1A1* expression [80], and it is possible that screening of the tumor cells as well as germline DNA may also be needed for a comprehensive irinotecan pharmacogenomic profile.

Conclusion

Although *UGT1A1**28 provides a compelling story for irinotecan toxicity, it is not the only answer. Variation in any gene involved in the irinotecan pathway (Figure 1) could play a role in either toxicity or response. As well as polymorphisms, either assessed singly or in the form of a haplotype, other genomic alterations, such as epigenetics, also need to be assessed to build a comprehensive pharmacogenomic profile. This may require assessing DNA from tumor tissue to analyze specific alterations in the tumor genome, alongside the more typical germline DNA screening. Currently, markers for irinotecan response are few, and many remain unvalidated. Further analysis, particularly of the pharmacodynamic genes, will hopefully identify the genetic basis of response to irinotecan.

Executive summary

- Irinotecan is approved, in combination, for the treatment of metastatic colorectal cancer. It is also used for treating other solid tumors such as ovarian and non-small-cell lung cancer.
- Severe toxicity from irinotecan occurs in up to 36% of patients.

Irinotecan pharmacokinetics

- A polymorphic dinucleotide repeat in the *UGT1A1* promoter region (*UGT1A1**28) is significantly associated with irinotecan toxicity.
- There is now a US FDA-approved test for *UGT1A1**28, and the irinotecan package insert contains warnings about *UGT1A1**28 and risk of toxicity.
- The *UGT1A1**28 association with irinotecan toxicity is dose dependent.
- Other *UGT1A* polymorphisms may also play a role in irinotecan toxicity, especially in populations with a low incidence of *UGT1A1**28.

- *ABCB1* polymorphisms have been associated with both toxicity and response.
- An *ABCC2* haplotype may predict irinotecan toxicity in patients who are not carriers of *UGT1A1**28.

Irinotecan pharmacodynamics

- Initial studies have shown that XRCC1 and TDP1 are associated with toxicity and response.

Future perspective

- Phase I studies aimed at determining *UGT1A1**28-dependent dosing of irinotecan will help to improve the use of irinotecan pharmacogenomics in clinical practice.
- Other pharmacogenomic studies, including expression panels and epigenetic markers, may prove to be useful indicators of outcome and toxicity to irinotecan.

Conclusion

- Although *UGT1A1**28 is a strong candidate as a pharmacogenomic marker for irinotecan toxicity, a panel of markers will be required in order to be as predictive as possible prior to irinotecan therapy selection or irinotecan dose selection.

Acknowledgments

Financial & competing interests disclosure Sharon Marsh is supported by the University of Alberta, Janelle M Hoskins is supported by the NIH Pharmacogenetics Research Network grant U01GM63340.

Bibliography

Papers of special note have been highlighted as:

■ ■ of considerable interest

1. Abang AM. The clinical pharmacology of topoisomerase I inhibitors. *Semin. Hematol* 1998;35(3 Suppl. 4):13–21. [PubMed: 9779877]
2. Rothenberg ML. The current status of irinotecan (CPT-11) in the United States. *Ann. NY Acad. Sci* 1996;803:272–281. [PubMed: 8993521]
3. Wall ME. Camptothecin and taxol: discovery to clinic. *Med. Res. Rev* 1998;18(5):299–314. [PubMed: 9735871]
4. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF. Preclinical evaluation of CPT-11 and its active metabolite SN-38. *Semin. Oncol* 1996;23(1 Suppl. 3):11–20. [PubMed: 8633248]
5. Devore R 3rd, Johnson D, Crawford J, Dimery I, Eckardt J, Eckhardt SG. Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. *Oncology (Williston Park)* 1998;12(8 Suppl. 6):79–83. [PubMed: 9726097]
6. Gershenson DM. Irinotecan in epithelial ovarian cancer. *Oncology (Williston Park)* 2002;16(5 Suppl. 5):29–31. [PubMed: 12109803]
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N. Engl. J. Med* 2004;350(23):2335–2342. [PubMed: 15175435]
8. Hoff PM, Pazdur R. Progress in the development of novel treatments for colorectal cancer. *Oncology* 2004;18(6):705–708. [PubMed: 15214591]

9. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. *J. Clin. Oncol* 2003;21(5):807–814. [PubMed: 12610178]
10. Evans WE, McLeod HL. Pharmacogenomics – drug disposition, drug targets, and side effects. *N. Engl. J. Med* 2003;348(6):538–549. [PubMed: 12571262]
11. Marsh S, McLeod HL. Cancer pharmacogenetics. *Br. J. Cancer* 2004;90(1):8–11. [PubMed: 14710198]
12. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. *Pharmacogenomics* 2004;5(7):835–843. [PubMed: 15469406]
13. Gong QH, Cho JW, Huang T, et al. Thirteen UDP glucuronosyltransferase genes are encoded at the human *UGT1* gene complex locus. *Pharmacogenetics* 2001;11(4):357–368. [PubMed: 11434514]
14. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. *Cancer Res* 2000;60(5):1189–1192. [PubMed: 10728672]
15. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. *Clin. Cancer Res* 2002;8(8):2605–2611. [PubMed: 12171891]
16. Zhang W, Xu G, McLeod HL. Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. *Appl. Immunohistochem. Mol. Morphol* 2002;10(4):374–380. [PubMed: 12607608]
17. Yano H, Kayukawa S, Iida S, et al. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. *Cancer Sci* 2008;99(11):2309–2314. [PubMed: 18771527]
18. Marsh S, Xiao M, Yu J, et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. *Genomics* 2004;84(4):661–668. [PubMed: 15475243]
19. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. *Clin. Pharmacol. Ther* 2004;76(6):528–535. [PubMed: 15592324]
20. Bellott R, Le Morvan V, Charasson V, et al. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. *Cancer Chemother. Pharmacol* 2008;61(3):481–488. [PubMed: 17483951]
21. Wu MH, Chen P, Remo BF, Cook EH Jr, Das S, Dolan ME. Characterization of multiple promoters in the human carboxylesterase 2 gene. *Pharmacogenetics* 2003;13(7):425–435. [PubMed: 12835618]
22. Geshi E, Kimura T, Yoshimura M, et al. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. *Hypertens Res* 2005;28(9):719–725. [PubMed: 16419644]
23. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. *Cancer Res* 1998;58(3):468–472. [PubMed: 9458091]
24. van der Bol JM, Mathijssen RH, Creemers GJ, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. *Clin. Cancer Res* 2010;16(2):736–742. [PubMed: 20068078]
25. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with *UGT1A1* polymorphisms. *Oncology (Williston Park)* 2003;17(5 Suppl. 5):52–55. [PubMed: 12800608]
26. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (*UGT1A1*) promoter: a balanced polymorphism for regulation of bilirubin metabolism? *Proc. Natl Acad. Sci. USA* 1998;95(14):8170–8174. [PubMed: 9653159]
27. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. *Cancer Res* 2000;60(24):6921–6926. [PubMed: 11156391]

28. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. *Cancer Res* 2000;60(4):950–956. [PubMed: 10706110]
29. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. *Pharmacogenetics* 1999;9(5):591–599. [PubMed: 10591539]
30. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of *in vitro* SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with *UGT1A1* promoter polymorphism. *Clin. Pharmacol. Ther* 1999;65(5):576–582. [PubMed: 10340924]
31. Iyer L, Das S, Janisch L, et al. *UGT1A1* *28 polymorphism as a determinant of irinotecan disposition and toxicity. *Pharmacogenomics J* 2002;2(1):43–47. [PubMed: 11990381]
32. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer; results from Intergroup Trial N9741. *J. Clin. Oncol.* 2010 DOI: 10.1200/JCO.2009.21.7943. (Epub ahead of print).
33. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J. Clin. Oncol* 2004;22(8):1382–1388. [PubMed: 15007088] ■■ Prospective study confirming the role of *UGT1A1* *28 in irinotecan toxicity.
34. Staessen JA, Kuznetsova T, Acceto R, et al. on behalf of the OASIS-HT Investigators: FDA clears Third Wave pharmacogenetic test. *Pharmacogenomics* 2005;6(7):671–672.
35. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. *Clin. Cancer Res* 2006;12(6):1658–1660. [PubMed: 16551845]
36. Marsh S, van Rooij T. Challenges of incorporating pharmacogenomics into clinical practice. *Gastrointest. Cancer Res* 2009;3(5):206–207. [PubMed: 20084163]
37. Ratain MJ, Innocenti F. Individualizing dosing of irinotecan. *Clin. Cancer Res* 2010;16(2):371–372. [PubMed: 20068075]
38. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. *UGT1A1* *28 genotype and irinotecan-induced neutropenia: dose matters. *J. Natl Cancer Inst* 2007;99(17):1290–1295. [PubMed: 17728214] ■■ Analysis showing that *UGT1A1* *28-related irinotecan toxicity is dependent on irinotecan dose.
39. Schulz C, Heinemann V, Schalhorn A, et al. *UGT1A1* gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. *World J. Gastroenterol* 2009;15(40):5058–5066. [PubMed: 19859999]
40. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven Phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. *J. Clin. Oncol* 2010;28(5):866–871. [PubMed: 20038727] ■■ Identifies the optimum dose of irinotecan based on genotype.
41. Hazama S, Nagashima A, Kondo H, et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the *UGT1A1* *28 polymorphism. *Cancer Sci* 2010;101(3):722–727. [PubMed: 20028383]
42. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (*UGT1A1*): hematologic and evolutionary implications. *Blood Cells Mol. Dis* 2003;31(1):98–101. [PubMed: 12850492]
43. Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among *UGT1A1* and transporter genes. *Proc. Am. Soc. Clin. Oncol* 2005;23:S16. (Abstract 2006).
44. Sai K, Saeki M, Saito Y, et al. *UGT1A1* haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. *Clin. Pharmacol. Ther* 2004;75(6):501–515. [PubMed: 15179405]
45. Hoskins JM, McLeod HL. The move from pharmacokinetics to pharmacodynamics. *Curr. Pharmacogenomics* 2006;4:39–46.
46. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic *ABCC2* transporter protein. *Clin. Pharmacol. Ther* 2007;81(1):42–49. [PubMed: 17185998]

47. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of *UGT1A* polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. *J. Clin. Oncol* 2006;24(15):2237–2244. [PubMed: 16636344]
48. Takano M, Kato M, Yoshikawa T, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. *Oncology* 2009;76(5):315–321. [PubMed: 19299905]
49. Jada SR, Lim R, Wong CI, et al. Role of *UGT1A1**6, *UGT1A1**28 and *ABCG2* c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. *Cancer Sci* 2007;98(9):1461–1467. [PubMed: 17627617]
50. Onoue M, Terada T, Kobayashi M, et al. *UGT1A1**6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. *Int. J. Clin. Oncol* 2009;14(2):136–142. [PubMed: 19390945]
51. Saito Y, Sai K, Maekawa K, et al. Close association of *UGT1A9* IVS1+399C>T with *UGT1A1**28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. *Drug Metab. Dispos* 2009;37(2):272–276. [PubMed: 18981166]
52. Carlini LE, Meropol NJ, Bever J, et al. *UGT1A7* and *UGT1A9* polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. *Clin. Cancer Res* 2005;11(3):1226–1236. [PubMed: 15709193]
53. Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. *J. Clin. Oncol* 2009;27(15):2419–2421. [PubMed: 19364959]
54. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the *UGT1A1*, *UGT1A7*, and *UGT1A9* genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. *J. Clin. Oncol* 2009;27(15):2457–2465. [PubMed: 19364970]
55. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. *Drug Resist. Update* 2003;6(2):71–84.
56. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. *Clin. Cancer Res* 2003;9(9):3246–3253. [PubMed: 12960109]
57. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. *J. Clin. Oncol* 2009;27(15):2530–2535. [PubMed: 19349543]
58. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of *ABCB1/MDR1* blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. *Pharmacogenetics* 2003;13(12):741–757. [PubMed: 14646693]
59. Glimelius B, Garmo H, Berglund A, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. *Pharmacogenomics J.* 2010 DOI: 10.1038/tpj.2010.10. (Epub ahead of print).
60. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. *Lung Cancer* 2009;63(1):115–120. [PubMed: 18221820]
61. Han JY, Lim HS, Yoo YK, et al. Associations of *ABCB1*, *ABCC2*, and *ABCG2* polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. *Cancer* 2007;110(1):138–147. [PubMed: 17534875]
62. Fujita K, Nagashima F, Yamamoto W, et al. Association of ATP-binding cassette, sub-family C, number 2 (*ABCC2*) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). *Biol. Pharm. Bull* 2008;31(11):2137–2142. [PubMed: 18981587]
63. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. *J. Clin. Oncol* 2009;27(16):2604–2614. [PubMed: 19349540]
64. Schellens JH, Maliepaard M, Scheper RJ, et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. *Ann. NY Acad. Sci* 2000;922:188–194. [PubMed: 11193894]

65. Candeil L, Gourdiér I, Peyron D, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. *Int. J. Cancer* 2004;109(6):848–854. [PubMed: 15027118]
66. Imai Y, Nakane M, Kage K, et al. *C421A* polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. *Mol. Cancer Ther* 2002;1(8):611–616. [PubMed: 12479221]
67. Sai K, Saito Y, Maekawa K, et al. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. *Cancer Chemother. Pharmacol* 2009;66(1):95–105. [PubMed: 19771428]
68. Park DJ, Stoecklacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A *Xeroderma pigmentosum* group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. *Cancer Res* 2001;61(24):8654–8658. [PubMed: 11751380]
69. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, Berger NA. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. *Cancer Commun* 1989;1(6):389–394. [PubMed: 2562007]
70. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. *Science* 1999;286(5439):552–555. [PubMed: 10521354]
71. Reid RJ, Fiorani P, Sugawara M, Bjornsti MA. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. *Proc. Natl Acad. Sci. USA* 1999;96(20):11440–11445. [PubMed: 10500195]
72. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor- κ B inhibition. *Cancer Res* 2001;61(9):3535–3540. [PubMed: 11325813]
73. Valente P, Arzani D, Cesario A, Margaritora S, Carbone E, Russo P. TNF increases camptothecin-induced apoptosis by inhibition of NF- κ B. *Eur. J. Cancer* 2003;39(10):1468–1477. [PubMed: 12826051]
74. Hoskins JM, Marcuello E, Altes A, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. *Clin. Cancer Res* 2008;14(6):1788–1796. [PubMed: 18347181]
75. Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. *Pharmacogenomics* 2009;10(7):1139–1146. [PubMed: 19604089]
76. Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. *J. Clin. Oncol* 2009;27(33):5519–5528. [PubMed: 19858398]
77. Artac M, Bozcuk H, Pehlivan S, et al. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. *J. Cancer Res. Clin. Oncol* 2009;136(6):803–809. [PubMed: 19908066]
78. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. *Cancer* 2009;115(17):3858–3867. [PubMed: 19517472] ■■ Pharmacoeconomic evaluation of *UGT1A1* *28 genotype screening.
79. Raynal C, Pascussi JM, Leguèl G, et al. Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. *Mol. Cancer* 2010;9:46. [PubMed: 20196838]
80. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. *BMC Mol. Biol* 2010;11:9. [PubMed: 20096102]
81. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. *Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J* 2001;1(3):167–170. [PubMed: 11908751]




Figure 1. Irinotecan cancer cell pathway

Reproduced with kind permission from PharmGKB and Stanford University [81].

Table 1

Summary of genes and variants from irinotecan pharmacogenomics studies.

Gene	Variant	dbSNP ID	Effect	Ref.
<i>ABCB1</i>	1236C>T	rs1128503	Decreased irinotecan clearance; risk of toxicity and reduced survival when in haplotype with 2677 and 3435	[56,58,59]
<i>ABCB1</i>	2677G>A/T	rs2032582	Risk of toxicity and reduced survival when in haplotype with 1236 and 3435	[58,59]
<i>ABCB1</i>	3435C>T	rs1045642	Increased toxicity; risk of toxicity and reduced survival when in haplotype with 1236 and 2677	[57–59]
<i>ABCC2</i>	–24C>T	rs717620	Increased response and survival with 3972; toxicity as part of <i>ABCC2</i> haplotype in patients without <i>GT1A1</i> *28	[46,61–63]
<i>ABCC2</i>	3972T>C	rs3740066	Increased response and survival with –24; toxicity as part of <i>ABCC2</i> haplotype in patients without <i>UGT1A1</i> *28	[43,46,60–63]
<i>ABCG2</i>	34G>A	rs2231137	Increased toxicity; no association with toxicity and outcome	[60,61]
<i>ABCG2</i>	421C>A; Q141K	rs2231142	Reduced expression; irinotecan resistance; toxicity with IVS12 +49G>T	[49,61,66,67]
<i>ABCG2</i>	IVS12+49G>T	rs3832043	Toxicity with 421C>A	[49,61,66,67]
<i>CES1</i>	–816A>C	Unknown	Altered <i>CES1</i> promoter activity	[22]
<i>CES2</i>	830C>G; –171C>G	rs11075646	No association with expression, catalytic activity, toxicity or outcome	[20]
<i>CYP3A4</i>	Activity		Altered irinotecan dosing requirement	[24]
<i>NR1I2</i>	Expression		Altered SN-38 glucuronidation	[79]
<i>TDP1</i>	IVS12+79T>G	rs2401863	Response; no toxicity association at higher doses	[74,75]
<i>UGT1A1</i>	–3156G>A	rs10929302	Increased risk of toxicity	[32,33]
<i>UGT1A1</i>	(TA) ₇ TAA, *28	rs8175347	Increased risk of toxicity; dose dependent	[32,33,38–41]
<i>UGT1A1</i>	G71R, *6	rs4148323	Increased risk of toxicity	[44,47]
<i>UGT1A7</i>	*2 (N129K and R131K)	rs17868323, rs17868324	SN-38 glucuronidation; response	[47,52]
<i>UGT1A7</i>	*3 (N129K, R131K and W208R)	rs17868323, rs17868324, rs11692021	SN-38 glucuronidation; increased risk of toxicity; altered response	[47,52,54]
<i>UGT1A9</i>	–118(dT)	rs3832043	SN-30 glucuronidation; response	[44,47,52,54]
<i>XRCC1</i>	Haplotype (–1149delGGCC, R399Q)	rs321329 rs25487	Response	[74]
<i>XRCC1</i>	R399Q	rs25487	No association with toxicity; association with response	[76,77]

dbSNP: SNP database